Medicine and Dentistry
Ovarian Cancer
100%
Malignant Neoplasm
33%
Neoplasm
31%
Krukenberg Tumor
30%
Uterine Cancer
23%
Oncology
22%
Overall Survival
22%
Gynecological Oncology
22%
Natural Killer Cell
22%
Diseases
17%
Biological Marker
17%
Progression Free Survival
15%
Hysterectomy
14%
Carboplatin
12%
Recurrent Disease
11%
Radiation Therapy
11%
Cancer
10%
Papanicolaou Stain
10%
Randomized Controlled Trial
9%
Kaplan Meier Method
9%
Cancer Cell
9%
CA-125
9%
Adjuvant Chemotherapy
8%
Female Genital Tract Cancer
8%
Immunotherapy
7%
Cervical Cancer
7%
Cervical Cancer Screening
7%
Genetic Counseling
7%
Intraperitoneal Chemotherapy
7%
Circulating Tumor Cell
7%
Patient Referral
7%
Bupivacaine
7%
Phase II Trials
7%
Arm
7%
In Vitro
6%
Quality of Life
6%
Cancer Therapy
6%
Adjuvant Therapy
6%
Transversus Abdominis Plane Block
6%
Hazard Ratio
6%
Breast Cancer
5%
Cytomegalovirus
5%
Cervix
5%
Cytotechnology
5%
Paclitaxel
5%
Retroperitoneal Lymph Node Dissection
5%
Recurrent Ovarian Cancer
5%
Mass Spectrum
5%
Genetic Risk
5%
DNA Mismatch Repair
5%
Keyphrases
Ovarian Cancer
80%
Natural Killer Cells
35%
Tumor
24%
Chemotherapy
23%
Endometrial Cancer
15%
Gynecologic Oncology Group
15%
Overall Survival
15%
NRG Oncology
14%
Phase II Trial
13%
Progression-free Survival
12%
Interleukin-15 (IL-15)
12%
Epithelial Ovarian Cancer
12%
Group Studies
12%
Advanced Ovarian Cancer
11%
Gynecologic Oncology
11%
Genetic Counseling
11%
Ovarian Cancer Cells
11%
Pap Test
10%
Ovarian Cancer Patients
10%
Prospective Randomized Trial
10%
Intraperitoneal Chemotherapy
10%
Carboplatin
10%
Engager
9%
Confidence Interval
9%
Carbohydrate Antigen 125 (CA125)
9%
Cervical Cancer
9%
Gynecologic Malignancies
8%
Adjuvant Chemotherapy
8%
Recurrent Ovarian Cancer
8%
Single Institution
8%
Cancer Immunotherapy
8%
Robotic Hysterectomy
8%
Gynecological Cancer
8%
Cervical Cancer Screening
7%
Cancer Patients
7%
Circulating Tumor Cells
7%
Sandwich Method
7%
Randomized Controlled Trial
7%
Transversus Abdominis Plane
7%
Ultrasound-guided
7%
Liposomal Bupivacaine
7%
Ovarian Carcinoma
7%
Primary Peritoneal Cancer
7%
Phase II Study
7%
Infiltration
6%
Transversus Abdominis Plane Block
6%
Radiotherapy
6%
Advanced Stage
6%
Adjuvant Therapy
5%
Chemoresistant
5%